Have lunch while learning about new product launches and treatment options during the Industry Theaters and Mini Industry Theaters, which take place in the Exhibit Hall. Complimentary boxed lunch provided by the ATS while supplies last. (Photo: R.C. Photographic Productions)
With increasing popularity of Industry Theaters, ATS 2015 has brought more offerings than ever before. Professionals have been leading a total of 19 Industry Theater and Mini Industry Theater discussions in the Exhibit Hall. Have lunch while learning about new product launches and treatment options. Complimentary boxed lunch will be provided by the ATS while supplies last.
Today
11:45 a.m. to 12:30 p.m.
Industry Theater 1
An Alternative Mode of Prostacyclin Delivery for the Treatment of PAH
(Open to U.S. attendees only)
Prostacyclin class therapy has been recommended for treatment of PAH for more than a decade. This session will provide a forum to discuss clinical and practical insights of an alternative delivery of a prostacyclin analogue.
Company: United Therapeutics Corporation
11:45 a.m. to 12:30 p.m.
Industry Theater 2
New Insights into the Management of COPD
(Open to U.S. attendees only)
This Industry Theater will focus on the importance of optimal bronchodilation in treating patients with COPD. Key points of emphasis will include residual symptoms despite treatment, the central role of bronchodilation in treating COPD, the potential additive effects of using a long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA), and the appropriate use of inhaled corticosteroids.
Speakers: Bartolome R. Celli, MD, Professor of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, and Donald A. Mahler, MD, Emeritus Professor of Medicine, Geisel School of Medicine at Dartmouth, Director, Pulmonary Function Laboratory, Dartmouth-Hitchcock Medical Center
Company: Novartis Pharmaceuticals
11:30 a.m. to Noon
Mini Industry Theater
Treatment of the Respiratory Manifestations of Symptomatic Sarcoidosis
This program will address the unmet need in the treatment of respiratory manifestations of sarcoidosis and introduce an FDA-approved treatment option.
Speaker: Robert P. Baughman, MD, University of Cincinnati Medical Center
Company: Mallinckrodt Pharmaceuticals
12:30 to 1 p.m.
Mini Industry Theater
Treatment of the Respiratory Manifestations of Symptomatic Sarcoidosis
This program will address the unmet need in the treatment of respiratory manifestations of sarcoidosis and introduce an FDA-approved treatment option.
Speaker: Daniel Culver, DO, Cleveland Clinic
Company: Mallinckrodt Pharmaceuticals
1:30 to 2 p.m.
Mini Industry Theater
When Struggling with COPD Symptoms: Assess Your Treatment Plan
The objective of this presentation is to provide pertinent, balanced information to healthcare professionals on the efficacy and safety of nebulized long-acting bronchodilator therapy for patients with COPD. It is designed to afford healthcare professionals the opportunity to review, evaluate and discuss the role of nebulized long-acting bronchodilator therapy as an option for patients with COPD, including chronic bronchitis and emphysema, in order to make informed treatment decisions for their patients.
Speaker: Sanjay Sethi, MD, FACP, Professor, Department of Medicine, Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, University at Buffalo, State University of New York, Buffalo, NY
Company: Sunovion Pharmaceuticals, Inc.